Abbott Laboratories (TSX:ABT)
Canada · Delayed Price · Currency is CAD 18.02
+0.10 (0.56%)
Sep 21, 2026, 3:44 PM EST
Abbott Laboratories Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 249,856 | 298,710 | 282,278 | 252,356 | 259,081 | 305,445 | |
Market Cap Growth | -23.41% | 5.82% | 11.86% | -2.60% | -15.18% | 27.78% |
Enterprise Value | 288,792 | 306,323 | 293,055 | 264,064 | 268,395 | 316,734 |
Last Close Price | 18.02 | 21.89 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 32.58 | 33.52 | 14.64 | 33.52 | 27.72 | 34.28 |
PS Ratio | 3.78 | 4.92 | 4.68 | 4.76 | 4.39 | 5.60 |
PB Ratio | 3.40 | 4.13 | 4.10 | 4.92 | 5.19 | 6.70 |
P/TBV Ratio | - | 9.65 | 10.96 | 31.28 | 55.76 | - |
P/FCF Ratio | 22.49 | 29.46 | 30.89 | 37.77 | 24.53 | 27.91 |
P/OCF Ratio | 17.76 | 22.77 | 22.92 | 26.32 | 19.98 | 22.92 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.42 | 5.04 | 4.86 | 4.99 | 4.54 | 5.81 |
EV/EBITDA Ratio | 17.06 | 18.57 | 19.01 | 19.11 | 16.02 | 19.64 |
EV/EBIT Ratio | 25.01 | 25.05 | 27.17 | 27.69 | 21.76 | 27.19 |
EV/FCF Ratio | 25.99 | 30.21 | 32.07 | 39.52 | 25.41 | 28.94 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.63 | 0.27 | 0.32 | 0.41 | 0.49 | 0.53 |
Debt / EBITDA Ratio | 2.71 | 1.14 | 1.38 | 1.48 | 1.41 | 1.47 |
Debt / FCF Ratio | 4.18 | 1.91 | 2.41 | 3.16 | 2.30 | 2.23 |
Net Debt / Equity Ratio | 0.52 | 0.10 | 0.15 | 0.22 | 0.21 | 0.25 |
Net Debt / EBITDA Ratio | 2.32 | 0.43 | 0.69 | 0.83 | 0.63 | 0.71 |
Net Debt / FCF Ratio | 3.47 | 0.70 | 1.16 | 1.72 | 1.00 | 1.04 |
Asset Turnover | 0.48 | 0.53 | 0.54 | 0.54 | 0.58 | 0.58 |
Inventory Turnover | 2.82 | 3.03 | 2.92 | 2.81 | 3.37 | 3.56 |
Quick Ratio | 0.80 | 1.02 | 1.05 | 1.00 | 1.06 | 1.28 |
Current Ratio | 1.38 | 1.58 | 1.67 | 1.64 | 1.63 | 1.85 |
Return on Equity (ROE) | 10.58% | 12.96% | 30.91% | 15.11% | 19.01% | 20.49% |
Return on Assets (ROA) | 5.33% | 6.63% | 6.06% | 6.11% | 7.61% | 7.79% |
Return on Invested Capital (ROIC) | 7.51% | 12.14% | 14.59% | 13.45% | 16.96% | 17.46% |
Return on Capital Employed (ROCE) | 9.00% | 12.70% | 11.10% | 12.20% | 15.50% | 14.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.07% | 3.00% | 6.83% | 3.00% | 3.62% | 2.93% |
FCF Yield | 4.45% | 3.39% | 3.24% | 2.65% | 4.08% | 3.58% |
Dividend Yield | 2.40% | 15.03% | - | - | - | - |
Payout Ratio | 78.54% | 63.09% | 28.62% | 62.13% | 47.73% | 45.28% |
Buyback Yield / Dilution | 0.08% | -0.06% | 0.06% | 0.85% | 1.40% | -0.17% |
Total Shareholder Return | 2.48% | 14.98% | 0.06% | 0.85% | 1.40% | -0.17% |